FDA approves Bayer’s Jivi
Bayer’s Jivi is indicated as a prophylactic treatment for hemophilia A, with an initial recommended regimen of twice weekly, with the ability to dose every five days, and to adjust to less or more frequent dosing based on a patient’s bleeding episode.